Evidence map›Paper›PMID 35557946›Full record

ArticleFrontiers in cell and developmental biology2022

Posology and Serum-/Xeno-Free Engineered Adipose Stromal Cells Cell Sheets.

Jun Ochiai, Larakaye Villanueva, Hope Niihara, Yutaka Niihara, Joan Oliva

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Role of Adipose-Derived Mesenchymal Stem Cells in Bone Regeneration.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun OchiaiEmmaus Life Sciences, Inc., Torrance, CA, United States.
Larakaye VillanuevaEmmaus Life Sciences, Inc., Torrance, CA, United States.
Hope NiiharaEmmaus Life Sciences, Inc., Torrance, CA, United States.
Yutaka NiiharaEmmaus Life Sciences, Inc., Torrance, CA, United States.
Joan OlivaEmmaus Life Sciences, Inc., Torrance, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Well-characterized adipose stem cells and chemically defined culture media are important factors that control the production of the cell sheet, used in translational medicine. In this study, we have developed and engineered multilayer adipose stem cell cell sheets (ASCCSs) using chemically defined/serum-free culture media: undifferentiated or differentiated into osteoblasts and chondrocytes. In addition, using the cell sheet transmittance, we estimated the number of cells per cell sheet. Undifferentiated ASCCSs were engineered in 10 days, using serum-free/xeno-free culture media. They were CD29

Indexed as

cell sheetsmesenchymal stem cellsmultilayerposologyserum-/xeno freetransmittance

Identifiers

PMID35557946
PMCPMC9086846

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.